59 results on '"Stathis M"'
Search Results
2. EmptyDropsMultiome discriminates real cells from background in single-cell multiomics assays
- Author
-
Stathis Megas, Valentina Lorenzi, and John C. Marioni
- Subjects
Multiomics ,Single-cell ,Method ,Biology (General) ,QH301-705.5 ,Genetics ,QH426-470 - Abstract
Abstract Multiomic droplet-based technologies allow different molecular modalities, such as chromatin accessibility and gene expression (scATAC-seq and scRNA-seq), to be probed in the same nucleus. We develop EmptyDropsMultiome, an approach that distinguishes true nuclei-containing droplets from background. Using simulations, we show that EmptyDropsMultiome has higher statistical power and accuracy than existing approaches, including CellRanger-arc and EmptyDrops. On real datasets, we observe that CellRanger-arc misses more than half of the nuclei identified by EmptyDropsMultiome and, moreover, is biased against certain cell types, some of which have a retrieval rate lower than 20%.
- Published
- 2024
- Full Text
- View/download PDF
3. Rate of binding of various inhibitors at the dopamine transporter in vivo
- Author
-
Stathis, M., Scheffel, U., Lever, S. Z., Boja, J. W., Kuhar, M. J., and Carroll, F. I.
- Published
- 1995
- Full Text
- View/download PDF
4. Low-Rank Methods in Event Detection With Subsampled Point-to-Subspace Proximity Tests
- Author
-
Jakub Marecek, Stathis Maroulis, Vana Kalogeraki, and Dimitrios Gunopulos
- Subjects
Multidimensional signal processing ,monitoring ,matrix completion ,point-to-subspace proximity ,probably approximately correct learning ,Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 - Abstract
Monitoring of streamed data to detect abnormal behaviour (variously known as event detection, anomaly detection, change detection, or outlier detection) underlies many applications, especially within the Internet of Things. There, one often collects data from a variety of sources, with asynchronous sampling, and missing data. In this setting, one can detect abnormal behavior using low-rank techniques. In particular, we assume that normal observations come from a low-rank subspace, prior to being corrupted by a uniformly distributed noise. Correspondingly, we aim to recover a representation of the subspace, and perform event detection by running point-to-subspace distance query for incoming data. We use a variant of low-rank factorisation, which considers interval uncertainty sets around “known entries”, on a suitable flattening of the input data to obtain a low-rank model. On-line, we compute the distance of incoming data to the low-rank normal subspace and update the subspace to keep it consistent with the seasonal changes present. For the distance computation, we consider subsampling. We bound the one-sided error as a function of the number of coordinates employed. In our computational experiments, we test the proposed algorithm on induction-loop data from Dublin, Ireland.
- Published
- 2022
- Full Text
- View/download PDF
5. 2d TQFTs and baby universes
- Author
-
John Gardiner and Stathis Megas
- Subjects
AdS-CFT Correspondence ,Models of Quantum Gravity ,Topological Field Theories ,Nuclear and particle physics. Atomic energy. Radioactivity ,QC770-798 - Abstract
Abstract In this work, we extend the 2d topological gravity model of [1] to have as its bulk action any open/closed TQFT obeying Atiyah’s axioms. The holographic duals of these topological gravity models are ensembles of 1d topological theories with random dimension. Specifically, we find that the TQFT Hilbert space splits into sectors, between which correlators of boundary observables factorize, and that the corresponding sectors of the boundary theory have dimensions independently chosen from different Poisson distributions. As a special case, we study in detail the gravity model built from the bulk action of 2d Dijkgraaf-Witten theory, with or without end-of-the-world branes, and for arbitrary finite group G. The dual of this Dijkgraaf-Witten gravity model can be interpreted as a 1d topological theory whose Hilbert space is a random representation of G and whose aforementioned sectors are labeled by the irreducible representations of G. These holographic interpretations of our gravity models require projecting out negative-norm states from the baby universe Hilbert space, which in [1] was achieved by the (only seemingly) ad hoc solution of adding a nonlocal boundary term to the bulk action. In order to place their solution in the completely local framework of a TQFT with defects, we couple the boundaries of the gravity model to an auxiliary 2d TQFT in a non-gravitational (i.e. fixed topology) region. In this framework, the difficulty of negative-norm states can be remedied in a local way by the introduction of a defect line between the gravitational and non-gravitational regions. The gravity model is then holographically dual to an ensemble of boundary conditions in an open/closed TQFT without gravity.
- Published
- 2021
- Full Text
- View/download PDF
6. Anomalous dimensions from thermal AdS partition functions
- Author
-
Per Kraus, Stathis Megas, and Allic Sivaramakrishnan
- Subjects
AdS-CFT Correspondence ,1/N Expansion ,Nuclear and particle physics. Atomic energy. Radioactivity ,QC770-798 - Abstract
Abstract We develop an efficient method for computing thermal partition functions of weakly coupled scalar fields in AdS. We consider quartic contact interactions and show how to evaluate the relevant two-loop vacuum diagrams without performing any explicit AdS integration, the key step being the use of Källén-Lehmann type identities. This leads to a simple method for extracting double-trace anomalous dimensions in any spacetime dimension, recovering known first-order results in a streamlined fashion.
- Published
- 2020
- Full Text
- View/download PDF
7. A Learning-Automata-Based Congestion-Aware Scheme for Energy-Efficient Elastic Optical Networks
- Author
-
Georgia A. Beletsioti, Georgios I. Papadimitriou, Petros Nicopolitidis, Emmanouel Varvarigos, and Stathis Mavridopoulos
- Subjects
Adaptivity ,elastic optical networks ,energy-efficiency ,learning automata ,metropolitan networks ,Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 - Abstract
The flexible nature of elastic optical networks (EONs) effectively uses spectral resources for optical communication by allocating the minimum required bandwidth to network connections. Since the energy consumption of such networks scales with the magnitude of bandwidth demand, addressing the issue of energy wastage is important. This fact has a profound impact on the design of efficient schemes for energy aware optical networks, and adaptivity arises as one of the most important properties of these networks. Learning Automata are Artificial Intelligence tools that have been used in networking algorithms, when adaptivity to the characteristics of the network environment can result in significantly improved network performance. In this work, a new adaptive power-aware algorithm is introduced, which selectively switches off bandwidth-variable optical transponders (BVTs) under low utilization conditions, to achieve energy efficiency. A novel adaptive scheme, which makes use of Learning Automata to significantly reduce the total energy consumption, while at the same time avoiding the onset of congestion, is proposed. The proposed scheme monitors network congestion, in terms of Bandwidth Blocking Probability (BBP), and the learning mechanism finds the optimal amount of energy-saving so that congestion is avoided, while at the same time significant energy savings are achieved. The proposed Learning Energy-Saving Algorithm (LESA) is evaluated via extensive simulation results, which indicate that it achieves an energy saving of up to 50%, compared to other energy efficient solutions.
- Published
- 2020
- Full Text
- View/download PDF
8. Additional binding mechanism of palonosetron to the 5-HT3 receptor versus first generation 5-HT3 receptor antagonists
- Author
-
Rojas, C., primary, Stathis, M., additional, Alt, J., additional, Rubenstein, E., additional, Cantoreggi, S., additional, Sebastiani, S., additional, and Slusher, B., additional
- Published
- 2007
- Full Text
- View/download PDF
9. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors
- Author
-
Scheffel, Ursula, primary, Lever, J.R., additional, Stathis, M., additional, and Ricaurte, G.A., additional
- Published
- 1992
- Full Text
- View/download PDF
10. High-Affinity No-Carrier-Added <SUP>99m</SUP>Tc-Labeled Chemotactic Peptides for Studies of Inflammation in Vivo
- Author
-
Baidoo, K. E., Scheffel, U., Stathis, M., Finley, P., Lever, S. Z., Zhan, Y., and Wagner, H. N., Jr.
- Abstract
Nα-for-Nle-Leu-Phe-Nle-Tyr-Lys, a chemotactic peptide that binds with high affinity to the chemoattractant receptor on granulocytes and monocytes, was labeled with 99mTc using the diaminedithiol (DADT) chelating system to coordinate the Tc. 99mTc labeling of the DADT-coupled peptide was accomplished in 84% overall yield (room temperature for 10 min) using [99mTc]glucoheptonate as the donor of prereduced Tc. HPLC analysis showed two major 99mTc-labeled peptide peaks, 99mTc−DADT−Pep-I and 99mTc−DADT−Pep-II, were obtained in a ratio of 1:0.85. Using an iodoacetamide-derivatized gel to remove unlabeled peptide from the 99mTc labeling mixtures, essentially no-carrier-added (nca) high-specific activity 99mTc-labeled chemotactic peptides were obtained. The 99Tc analogues of the peptides were synthesized (72% yield) in a similar fashion and correlated with 99mTc complexes I and II by HPLC. In vitro competitive receptor binding assays of the isolated 99Tc analogues were performed against the tritiated chemotactic peptide [3H]N-for-Met-Leu-Phe ([3H]fMLF) using isolated granulocytes. The 99Tc-derivatized peptides showed similar binding affinities to the chemoattractant receptor as the unlabeled Nα-for-Nle-Leu-Phe-Nle-Tyr-Lys. The nca 99mTc-labeled peptides gave high contrast images of experimental inflammation in rabbits without causing neutropenia. Thus, it is feasible to attach the Tc−DADT chelate to low-molecular weight receptor binding chemotactic peptides and retain substantial binding to the receptor. Chemotactic peptides labeled with 99mTc via the DADT ligand system have the potential for imaging focal sites of inflammation without toxic effects, an important consideration in the successful utilization of chemotactic peptide agonists.
- Published
- 1998
11. In vivo labeling of cocaine binding sites on dopamine transporters with [3H]WIN 35,428.
- Author
-
Scheffel, U, Pögün, S, Stathis, M, Boja, J W, and Kuhar, M J
- Abstract
After in vivo administration, [3H]WIN 35,428 accumulated in mouse brain regions containing dopaminergic nerve terminals. The highest accumulation was in the striatum and it peaked between 30 and 60 min. The accumulation was saturable with increasing doses of WIN 35,428, and was blocked by compounds that bind to the dopamine transporter. Paroxetine, a drug that blocks serotonin transporters, had no effect. Moreover, the in vivo potency of cocaine analogs correlated with their in vitro potency. Thus, [3H]WIN 35,428 is a suitable ligand for labeling cocaine receptors associated with dopamine transporters in vivo.
- Published
- 1991
12. Synthesis and in vivo studies of a selective ligand for the dopamine transporter 3 -(4-[^1^2^5I]iodophenyl) tropan 2 -carboxylic acid isopropyl ester ([^1^2^5I]RTI-121)
- Author
-
Lever, J. R., Scheffel, U., Stathis, M., Seltzman, H. H., Wyrick, C. D., Abraham, P., Parham, K., Thomas, B. F., Boja, J. W., and Kuhar, M. J.
- Published
- 1996
- Full Text
- View/download PDF
13. The Prophylaxis of Deep Vein Thrombosis with Low-Dose Heparin: A Trial.
- Author
-
Propsting, J., Williams, O., Stathis, M., and Mccaffrey, J. F.
- Published
- 1974
- Full Text
- View/download PDF
14. The Prophylaxis of Deep Vein Thrombosis with Low-Dose Heparin: A Trial
- Author
-
Propsting, J., primary, Williams, O., additional, Stathis, M., additional, and Mccaffrey, J. F., additional
- Published
- 1974
- Full Text
- View/download PDF
15. Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies
- Author
-
Ebenezer Gigi J, Zhao Ming, Rudek Michelle A, Polydefkis Michael, Stathis Marigo, Rojas Camilo, and Slusher Barbara S
- Subjects
Medicine - Abstract
Abstract Background Glutamate excitotoxicity is thought to be involved in the pathogenesis of neurodegenerative disease. One potential source of glutamate is N-acetyl-aspartyl-glutamate (NAAG) which is hydrolyzed to glutamate and N-acetyl-aspartate (NAA) in a reaction catalyzed by glutamate carboxypeptidase (GCP). As a result, GCP inhibition is thought to be beneficial for the treatment of neurodegenerative diseases where excess glutamate is presumed pathogenic. Both pharmacological and genetic inhibition of GCP has shown therapeutic utility in preclinical models and this has led to GCP inhibitors being pursued for the treatment of nervous system disorders in human clinical trials. Specifically, GCP inhibitors are currently being developed for peripheral neuropathy and neuropathic pain. The purpose of this study was to develop a pharmacodynamic (PD) marker assay to use in clinical development. The PD marker will determine the effect of GCP inhibitors on GCP enzymatic activity in human skin as measure of inhibition in peripheral nerve and help predict drug doses required to elicit pharmacologic responses. Methods GCP activity was first characterized in both human skin and rat paw pads. GCP activity was then monitored in both rodent paw pads and sciatic nerve from the same animals following peripheral administration of various doses of GCP inhibitor. Significant differences among measurements were determined using two-tailed distribution, equal variance student's t test. Results We describe for the first time, a direct and quantifiable assay to evaluate GCP enzymatic activity in human skin biopsy samples. In addition, we show that GCP activity in skin is responsive to pharmacological manipulation; GCP activity in rodent paws was inhibited in a dose response manner following peripheral administration of a potent and selective GCP inhibitor. Inhibition of GCP activity in rat paw pads was shown to correlate to inhibition of GCP activity in peripheral nerve. Conclusion Monitoring GCP activity in human skin after administration of GCP inhibitors could be readily used as PD marker in the clinical development of GCP inhibitors. Enzymatic activity provides a simple and direct measurement of GCP activity from tissue samples easily assessable in human subjects.
- Published
- 2011
- Full Text
- View/download PDF
16. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT 2 receptors
- Author
-
Scheffel, Ursula, Lever, J.R., Stathis, M., and Ricaurte, G.A.
- Published
- 1992
- Full Text
- View/download PDF
17. [^3h]A-69024: A Non-benzazepine Ligand for in Vitro and in Vivo Studies of Dopamine D1 Receptors
- Author
-
Kassiou, M., Scheffel, U. A., Musachio, J. L., and Stathis, M.
- Published
- 1995
- Full Text
- View/download PDF
18. Creating a comprehensive research strategy for cutaneous neurofibromas.
- Author
-
Blakeley JO, Wolkenstein P, Widemann BC, Lee J, Le LQ, Jackson R, Stathis M, and Verma SK
- Subjects
- Clinical Trials as Topic, Dermatology, Humans, Neurofibroma complications, Neurology, Research Design, Skin Neoplasms complications, Neurofibroma therapy, Neurofibromatosis 1 complications, Skin Neoplasms therapy
- Abstract
Objective: Outside of procedural-based methods, there are currently no established medical treatments for cutaneous neurofibroma (cNF), which afflict up to 99% of patients with NF1. Further, adult patients often report cNF are the greatest burden of living with NF1. The Neurofibromatosis Therapeutic Acceleration Program (NTAP) launched a think tank to address core questions to facilitate development of effective therapeutics for cNF in people with NF1., Methods: Experts (with and without explicit experience with NF1 or cNF) from multiple scientific and medical disciplines, representing the ranks of academia, industry, and government agencies, were invited to become a member of a team addressing a specific subset of questions pertinent to cNF. Teams met monthly to review published and unpublished materials, and created summaries about the material known and unknown that may influence therapeutic development for cNF. Teams prioritized questions and organized supporting data, which was presented to the entire body of experts by each team at a research summit., Results: Four themes were identified as being relevant to creating a comprehensive research strategy for cNF: (1) establishing definitions of cNF, (2) determining the biology of cNF with respect to tumor initiation, progression, and maintenance, (3) outlining the factors that guide therapies development, and (4) defining core considerations for clinical trials design and optimization for cNF., Conclusion: Considerations and key questions for each of the thematic areas were identified and provided basis for a request for applications launched by NTAP focused on cNF and are described in the accompanying articles of this supplement., (© 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2018
- Full Text
- View/download PDF
19. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.
- Author
-
Ferrer M, Gosline SJC, Stathis M, Zhang X, Guo X, Guha R, Ryman DA, Wallace MR, Kasch-Semenza L, Hao H, Ingersoll R, Mohr D, Thomas C, Verma S, Guinney J, and Blakeley JO
- Subjects
- Antineoplastic Agents therapeutic use, Cell Line, Tumor, Humans, Neurofibroma, Plexiform genetics, Neurofibroma, Plexiform pathology, Neurofibroma, Plexiform therapy, Gene Expression Profiling, Neurofibromatosis 1 genetics, Neurofibromatosis 1 pathology, Neurofibromatosis 1 therapy, Schwann Cells
- Abstract
Neurofibromatosis type I (NF1) is an autosomal dominant genetic condition characterized by peripheral nervous system tumors (PNSTs), including plexiform neurofibromas (pNFs) that cause nerve dysfunction, deformity, pain damage to adjacent structures, and can undergo malignant transformation. There are no effective therapies to prevent or treat pNFs. Drug discovery efforts are slowed by the 'benign' nature of the Schwann cells that are the progenitor cells of pNF. In this work we characterize a set of pNF-derived cell lines at the genomic level (via SNP Arrays, RNAseq, and Whole Exome- Sequencing), and carry out dose response-based quantitative high-throughput screening (qHTS) with a collection of 1,912 oncology-focused compounds in a 1536-well microplate cell proliferation assays. Through the characterization and screening of NF1
-/- , NF1+/+ and NF1+/- Schwann cell lines, this resource introduces novel therapeutic avenues for the development for NF1 associated pNF as well as all solid tumors with NF1 somatic mutations. The integrated data sets are openly available for further analysis at http://www.synapse.org/pnfCellCulture.- Published
- 2018
- Full Text
- View/download PDF
20. The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site.
- Author
-
Rojas C, Stathis M, Coughlin JM, Pomper M, and Slusher BS
- Subjects
- Binding Sites, Genotype, Humans, Receptors, GABA analysis, Neuroimaging methods, Positron-Emission Tomography methods, Radiopharmaceuticals chemistry, Receptors, GABA chemistry, Receptors, GABA genetics
- Abstract
[
11 C]-PK11195 (PK11195) has been widely used with positron emission tomography (PET) to assess levels of the translocator protein 18 kDa (TSPO) as a marker of neuroinflammation. Recent ligands, such as [11 C]-PBR28 and [11 C]-DPA713, have improved signal-to-noise ratio and specificity for TSPO over PK11195. However, these second generation radiotracers exhibit binding differences due to a single polymorphism (rs6971) that leads to three genotypes: C/C, C/T and T/T associated with high, mixed and low binding affinities, respectively. Here we report that [3 H]-DPA-713 in the presence of cholesterol or PK11195 has an accelerated dissociation rate from TSPO in platelets isolated from individuals with the T/T genotype. This allosteric interaction was not observed in platelets isolated from individuals with the C/C or C/T genotype. The results provide a molecular rationale for low binding affinity of T/T TSPO and further support the exclusion of these subjects from PET imaging studies using second generation TSPO ligands.- Published
- 2018
- Full Text
- View/download PDF
21. Development of a primary microglia screening assay and its use to characterize inhibition of system x c - by erastin and its analogs.
- Author
-
Figuera-Losada M, Thomas AG, Stathis M, Stockwell BR, Rojas C, and Slusher BS
- Abstract
The inflammatory response in the central nervous system involves activated microglia. Under normal conditions they remove damaged neurons by phagocytosis. On the other hand, neurodegenerative diseases are thought to involve chronic microglia activation resulting in release of excess glutamate, proinflammatory cytokines and reactive oxygen species, leading to neuronal death. System x
C - cystine/glutamate antiporter (SXC), a sodium independent heterodimeric transporter found in microglia and astrocytes in the CNS, imports cystine into the cell and exports glutamate. SXC has been shown to be upregulated in neurodegenerative diseases including multiple sclerosis, ALS, neuroAIDS Parkinson's disease and Alzheimer's disease. Consequently, SXC inhibitors could be of use in the treatment of diseases characterized by neuroinflammation and glutamate excitotoxicity. We report on the optimization of a primary microglia-based assay to screen for SXC inhibitors. Rat primary microglia were activated using lipopolysaccharides (LPS) and glutamate release and cystine uptake were monitored by fluorescence and radioactivity respectively. LPS-induced glutamate release increased with increasing cell density, time of incubation and LPS concentration. Conditions to screen for SXC inhibitors were optimized in 96-well format and subsequently used to evaluate SXC inhibitors. Known SXC inhibitors sulfasalazine, S-4CPG and erastin blocked glutamate release and cystine uptake while R-4CPG, the inactive enantiomer of S-4CPG, failed to inhibit glutamate release or cystine transport. In addition, several erastin analogs were evaluated using primary microglia and found to have EC50 values in agreement with previous studies using established cell lines.- Published
- 2017
- Full Text
- View/download PDF
22. FOLH1 /GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities.
- Author
-
Rais R, Jiang W, Zhai H, Wozniak KM, Stathis M, Hollinger KR, Thomas AG, Rojas C, Vornov JJ, Marohn M, Li X, and Slusher BS
- Abstract
Recent gene-profiling analyses showed significant upregulation of the folate hydrolase ( FOLH1 ) gene in the affected intestinal mucosa of patients with inflammatory bowel disease (IBD). The FOLH1 gene encodes a type II transmembrane glycoprotein termed glutamate carboxypeptidase II (GCPII). To establish that the previously reported increased gene expression was functional, we quantified the glutamate carboxypeptidase enzymatic activity in 31 surgical specimens and report a robust 2.8- to 41-fold increase in enzymatic activity in the affected intestinal mucosa of IBD patients compared with an uninvolved area in the same patients or intestinal mucosa from healthy controls. Using a human-to-mouse approach, we next showed a similar enzymatic increase in two well-validated IBD murine models and evaluated the therapeutic effect of the potent FOLH1 / GCPII inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) (IC
50 = 300 pM). In the dextran sodium sulfate (DSS) colitis model, 2-PMPA inhibited the GCPII activity in the colonic mucosa by over 90% and substantially reduced the disease activity. The significance of the target was confirmed in FOLH1-/- mice who exhibited resistance to DSS treatment. In the murine IL-10-/- model of spontaneous colitis, daily 2-PMPA treatment also significantly reduced both macroscopic and microscopic disease severity. These results provide the first evidence of FOLH1 /GCPII enzymatic inhibition as a therapeutic option for IBD.- Published
- 2016
- Full Text
- View/download PDF
23. Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold.
- Author
-
Zimmermann SC, Wolf EF, Luu A, Thomas AG, Stathis M, Poore B, Nguyen C, Le A, Rojas C, Slusher BS, and Tsukamoto T
- Abstract
A series of allosteric kidney-type glutaminase (GLS) inhibitors were designed and synthesized using 1,4-di(5-amino-1,3,4-thiadiazol-2-yl)butane as a core scaffold. A variety of modified phenylacetyl groups were incorporated into the 5-amino group of the two thiadiazole rings in an attempt to facilitate additional binding interactions with the allosteric binding site of GLS. Among the newly synthesized compounds, 4-hydroxy-N-[5-[4-[5-[(2-phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]butyl]-1,3,4-thiadiazol-2-yl]-benzeneacetamide, 2m, potently inhibited GLS with an IC50 value of 70 nM, although it did not exhibit time-dependency as seen with CB-839. Antiproliferative effects of 2m on human breast cancer lines will be also presented in comparison with those observed with CB-839.
- Published
- 2016
- Full Text
- View/download PDF
24. Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration.
- Author
-
Rais R, Wozniak K, Wu Y, Niwa M, Stathis M, Alt J, Giroux M, Sawa A, Rojas C, and Slusher BS
- Subjects
- Administration, Intranasal, Animals, Area Under Curve, Cerebellar Cortex metabolism, Chromatography, High Pressure Liquid, Glutamate Carboxypeptidase II metabolism, Glutarates administration & dosage, Glutarates analysis, Glutarates pharmacokinetics, Half-Life, Injections, Intraperitoneal, Macaca fascicularis, Male, Olfactory Bulb metabolism, Organophosphorus Compounds analysis, Organophosphorus Compounds pharmacokinetics, ROC Curve, Rats, Rats, Wistar, Sulfhydryl Compounds administration & dosage, Sulfhydryl Compounds analysis, Sulfhydryl Compounds pharmacokinetics, Tandem Mass Spectrometry, Central Nervous System metabolism, Glutamate Carboxypeptidase II antagonists & inhibitors, Organophosphorus Compounds administration & dosage
- Abstract
Glutamate carboxypeptidase II (GCP-II) is a brain metallopeptidase that hydrolyzes the abundant neuropeptide N-acetyl-aspartyl-glutamate (NAAG) to NAA and glutamate. Small molecule GCP-II inhibitors increase brain NAAG, which activates mGluR3, decreases glutamate, and provide therapeutic utility in a variety of preclinical models of neurodegenerative diseases wherein excess glutamate is presumed pathogenic. Unfortunately no GCP-II inhibitor has advanced clinically, largely due to their highly polar nature resulting in insufficient oral bioavailability and limited brain penetration. Herein we report a non-invasive route for delivery of GCP-II inhibitors to the brain via intranasal (i.n.) administration. Three structurally distinct classes of GCP-II inhibitors were evaluated including DCMC (urea-based), 2-MPPA (thiol-based) and 2-PMPA (phosphonate-based). While all showed some brain penetration following i.n. administration, 2-PMPA exhibited the highest levels and was chosen for further evaluation. Compared to intraperitoneal (i.p.) administration, equivalent doses of i.n. administered 2-PMPA resulted in similar plasma exposures (AUC0-t, i.n./AUC0-t, i.p. = 1.0) but dramatically enhanced brain exposures in the olfactory bulb (AUC0-t, i.n./AUC0-t, i.p. = 67), cortex (AUC0-t, i.n./AUC0-t, i.p. = 46) and cerebellum (AUC0-t, i.n./AUC0-t, i.p. = 6.3). Following i.n. administration, the brain tissue to plasma ratio based on AUC0-t in the olfactory bulb, cortex, and cerebellum were 1.49, 0.71 and 0.10, respectively, compared to an i.p. brain tissue to plasma ratio of less than 0.02 in all areas. Furthermore, i.n. administration of 2-PMPA resulted in complete inhibition of brain GCP-II enzymatic activity ex-vivo confirming target engagement. Lastly, because the rodent nasal system is not similar to humans, we evaluated i.n. 2-PMPA also in a non-human primate. We report that i.n. 2-PMPA provides selective brain delivery with micromolar concentrations. These studies support intranasal delivery of 2-PMPA to deliver therapeutic concentrations in the brain and may facilitate its clinical development.
- Published
- 2015
- Full Text
- View/download PDF
25. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties.
- Author
-
Figuera-Losada M, Stathis M, Dorskind JM, Thomas AG, Bandaru VV, Yoo SW, Westwood NJ, Rogers GW, McArthur JC, Haughey NJ, Slusher BS, and Rojas C
- Subjects
- Animals, Cattle, Cell Death drug effects, Cell Survival drug effects, Ceramides biosynthesis, Cytokines pharmacology, Dendrites drug effects, Dendrites pathology, Drug Evaluation, Preclinical, Enzyme Assays, Enzyme Inhibitors pharmacology, Fluorescence, HEK293 Cells, Hippocampus pathology, Humans, Interleukin-1beta pharmacology, Naphthalenes chemistry, Neurons drug effects, Neurons metabolism, Neuroprotective Agents chemistry, Pyrimidinones chemistry, Radioactivity, Rats, Sprague-Dawley, Recombinant Proteins pharmacology, Sphingomyelin Phosphodiesterase metabolism, Structure-Activity Relationship, Tumor Necrosis Factor-alpha pharmacology, Naphthalenes pharmacology, Neuroprotective Agents pharmacology, Pyrimidinones pharmacology, Sphingomyelin Phosphodiesterase antagonists & inhibitors
- Abstract
Ceramide is a bioactive lipid that plays an important role in stress responses leading to apoptosis, cell growth arrest and differentiation. Ceramide production is due in part to sphingomyelin hydrolysis by sphingomyelinases. In brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increases in its activity and expression have been associated with pro-inflammatory conditions observed in Alzheimer's disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Increased nSMase2 activity translates into higher ceramide levels and neuronal cell death, which can be prevented by chemical or genetic inhibition of nSMase2 activity or expression. However, to date, there are no soluble, specific and potent small molecule inhibitor tool compounds for in vivo studies or as a starting point for medicinal chemistry optimization. Moreover, the majority of the known inhibitors were identified using bacterial, bovine or rat nSMase2. In an attempt to identify new inhibitor scaffolds, two activity assays were optimized as screening platform using the recombinant human enzyme. First, active hits were identified using a fluorescence-based high throughput compatible assay. Then, hits were confirmed using a 14C sphingomyelin-based direct activity assay. Pharmacologically active compounds and approved drugs were screened using this strategy which led to the identification of cambinol as a novel uncompetitive nSMase2 inhibitor (Ki = 7 μM). The inhibitory activity of cambinol for nSMase2 was approximately 10-fold more potent than for its previously known target, silence information regulator 1 and 2 (SIRT1/2). Cambinol decreased tumor necrosis factor-α or interleukin-1 β-induced increases of ceramide and cell death in primary neurons. A preliminary study of cambinol structure and activity allowed the identification of the main structural features required for nSMase2 inhibition. Cambinol and its analogs may be useful as nSMase2 inhibitor tool compounds to prevent ceramide-dependent neurodegeneration.
- Published
- 2015
- Full Text
- View/download PDF
26. Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.
- Author
-
Thomas AG, Stathis M, Rojas C, and Slusher BS
- Subjects
- Acids pharmacology, Animals, Cell Line, Dose-Response Relationship, Drug, Drug Administration Schedule, HEK293 Cells, Humans, Mice, Neuroblastoma pathology, Palonosetron, Peptide Hydrolases pharmacology, Protein Binding drug effects, Protein Transport drug effects, Rats, Receptors, Neurokinin-1 genetics, Time Factors, Tritium pharmacokinetics, Isoquinolines pharmacology, Neurokinin-1 Receptor Antagonists pharmacology, Pyridines pharmacology, Quinuclidines pharmacology, Receptors, Neurokinin-1 metabolism, Serotonin Antagonists pharmacology
- Abstract
Current therapy for chemotherapy-induced nausea and vomiting includes the use of both 5-HT3 and NK1 receptor antagonists. Acute emesis has largely been alleviated with the use of 5-HT3 receptor antagonists, while an improvement in preventing delayed emesis has been achieved with NK1 receptor antagonists. Delayed emesis, however, remains a problem with a significant portion of cancer patients receiving highly emetogenic chemotherapy. Like other drugs in its class, palonosetron, a 5-HT3 receptor antagonist, has shown efficacy against acute emesis. However, palonosetron has also shown consistent improvement in the suppression of delayed emesis. Since both 5-HT3 and NK1 receptor antagonists are often simultaneously administered to patients, the question remains if palonosetron's effect on delayed emesis would remain distinct when co-administered with an NK1 receptor antagonist. Recent mechanistic studies using NG108-15 cells have shown that palonosetron and netupitant, an NK1 receptor antagonist currently in phase 3 clinical trials, exhibited synergistic effects when inhibiting the substance P response. The present studies showed that both netupitant and palonosetron-induced NK1 receptor internalization in NG108-15 cells and that when used together receptor internalization was additive. Palonosetron-induced NK1 receptor internalization was dependent on the presence of the 5-HT3 receptor. Results provide a possible explanation for palonosetron's enhancement of the inhibition of the SP response and suggest that the effect of palonosetron and NK1 receptor antagonists on prevention of delayed emesis could be additive.
- Published
- 2014
- Full Text
- View/download PDF
27. Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV.
- Author
-
Coughlin JM, Wang Y, Ma S, Yue C, Kim PK, Adams AV, Roosa HV, Gage KL, Stathis M, Rais R, Rojas C, McGlothan JL, Watkins CC, Sacktor N, Guilarte TR, Zhou Y, Sawa A, Slusher BS, Caffo B, Kassiou M, Endres CJ, and Pomper MG
- Subjects
- AIDS Dementia Complex therapy, Acetamides, Adult, Anti-Retroviral Agents therapeutic use, Biomarkers metabolism, Brain diagnostic imaging, Brain metabolism, Brain virology, Carbon Isotopes, Genotype, Humans, Microglia metabolism, Middle Aged, Neuropsychological Tests, Phenotype, Pyrazoles, Pyrimidines, Receptors, GABA genetics, Young Adult, AIDS Dementia Complex diagnostic imaging, AIDS Dementia Complex metabolism, Positron-Emission Tomography methods, Receptors, GABA metabolism
- Abstract
Imaging the brain distribution of translocator protein (TSPO), a putative biomarker for glial cell activation and neuroinflammation, may inform management of individuals infected with HIV by uncovering regional abnormalities related to neurocognitive deficits and enable non-invasive therapeutic monitoring. Using the second-generation TSPO-targeted radiotracer, [(11)C]DPA-713, we conducted a positron emission tomography (PET) study to compare the brains of 12 healthy human subjects to those of 23 individuals with HIV who were effectively treated with combination antiretroviral therapy (cART). Compared to PET data from age-matched healthy control subjects, [(11)C]DPA-713 PET of individuals infected with HIV demonstrated significantly higher volume-of-distribution (VT) ratios in white matter, cingulate cortex, and supramarginal gyrus, relative to overall gray matter VT, suggesting localized glial cell activation in susceptible regions. Regional TSPO abnormalities were evident within a sub-cohort of neuro-asymptomatic HIV subjects, and an increase in the VT ratio within frontal cortex was specifically linked to individuals affected with HIV-associated dementia. These findings were enabled by employing a gray matter normalization approach for PET data quantification, which improved test-retest reproducibility, intra-class correlation within the healthy control cohort, and sensitivity of uncovering abnormal regional findings.
- Published
- 2014
- Full Text
- View/download PDF
28. Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
- Author
-
Alt J, Stathis M, Rojas C, and Slusher B
- Subjects
- Antigens, Surface genetics, Biocatalysis, Dipeptides metabolism, Glutamate Carboxypeptidase II genetics, Humans, Hydrolysis, Mass Spectrometry methods, Neprilysin metabolism, Peptide Fragments metabolism, Proteolysis, Recombinant Proteins metabolism, Tritium, Amyloid beta-Peptides metabolism, Antigens, Surface metabolism, Glutamate Carboxypeptidase II metabolism
- Abstract
Glutamate carboxypeptidase II (GCPII) is an exopeptidase that catalyzes the hydrolysis of N-acetylated aspartate-glutamate (NAAG) to N-acetyl aspartate (NAA) and glutamate. Consequently, GCPII inhibition has been of interest for the treatment of central and peripheral nervous system diseases associated with excess glutamate. Recently, it was reported that GCPII can also serve as an endopeptidase cleaving amyloid β (Aβ) peptides and that its inhibition could increase the risk of Alzheimer's disease by increasing brain Aβ levels. This study aimed to corroborate and extend these new findings. We incubated Aβ peptides (20 μM) with human recombinant GCPII (300 ng/ml) and monitored the appearance of degradation products by mass spectrometry. Aβ peptides remained intact after 18 h incubation with GCPII. Under the same experimental conditions, Aβ1-40 (20 μM) was incubated with neprilysin (300 ng/ml), an endopeptidase known to hydrolyze Aβ1-40 and the expected cleavage products were observed. GCPII was confirmed active by catalyzing the complete hydrolysis of NAAG (100 μM). We also studied the hydrolysis of [(3)H]-NAAG (30 nM) catalyzed by GCPII (40 pM) in the presence of Aβ peptides (picomolar to micromolar range). The addition of Aβ peptides did not alter [(3)H]-NAAG hydrolysis. We conclude that GCPII is not an amyloid peptide-degrading enzyme.
- Published
- 2013
- Full Text
- View/download PDF
29. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.
- Author
-
Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, and Pomper MG
- Subjects
- Animals, Carboxylic Acids chemistry, Disease Models, Animal, Fluorescent Dyes pharmacokinetics, Fluorescent Dyes pharmacology, Glutamate Carboxypeptidase II metabolism, Humans, Kinetics, Lysine analogs & derivatives, Male, Membrane Glycoproteins metabolism, Mice, Mice, Nude, Molecular Imaging instrumentation, Molecular Weight, Polyethylene Glycols chemistry, Prostate drug effects, Prostate metabolism, Prostatic Neoplasms metabolism, Spectroscopy, Near-Infrared instrumentation, Fluorescent Dyes chemical synthesis, Glutamate Carboxypeptidase II analysis, Membrane Glycoproteins analysis, Molecular Imaging methods, Prostate pathology, Prostatic Neoplasms pathology, Spectroscopy, Near-Infrared methods
- Abstract
Targeted near-infrared (NIR) optical imaging can be used in vivo to detect specific tissues, including malignant cells. A series of NIR fluorescent ligands targeting the prostate-specific membrane antigen (PSMA) was synthesized and each compound was tested for its ability to image PSMA+ tissues in experimental models of prostate cancer. The agents were prepared by conjugating commercially available active esters of NIR dyes, including IRDye800CW, IRDye800RS, Cy5.5, Cy7, or a derivative of indocyanine green (ICG) to the terminal amine group of (S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid 1, (14S,18S)-1-amino-8,16-dioxo-3,6-dioxa-9,15,17-triazaicosane-14,18,20-tricarboxylic acid 2 and (3S,7S)-26-amino-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acid 3. The K(i) values for the dye-inhibitor conjugates ranged from 1 to 700 pM. All compounds proved capable of imaging PSMA+ tumors selectively to varying degrees depending on the choice of fluorophore and linker. The highest tumor uptake was observed with IRDye800CW employing a poly(ethylene glycol) or lysine-suberate linker, as in 800CW-2 and 800CW-3, while the highest tumor to nontarget tissue ratios were obtained for Cy7 with these same linkers, as in Cy7-2 and Cy7-3. Compounds 2 and 3 provide useful scaffolds for targeting of PSMA+ tissues in vivo and should be useful for preparing NIR dye conjugates designed specifically for clinical intraoperative optical imaging devices.
- Published
- 2012
- Full Text
- View/download PDF
30. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
- Author
-
Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, Alt J, Rais R, Rojas C, Gao P, Xiang Y, Dang CV, Slusher BS, and Tsukamoto T
- Subjects
- Enzyme Inhibitors chemical synthesis, Magnetic Resonance Spectroscopy, Models, Molecular, Sulfides chemical synthesis, Thiadiazoles chemical synthesis, Drug Design, Enzyme Inhibitors chemistry, Enzyme Inhibitors pharmacology, Glutaminase antagonists & inhibitors, Sulfides chemistry, Sulfides pharmacology, Thiadiazoles chemistry, Thiadiazoles pharmacology
- Abstract
Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a molecular probe to determine the therapeutic potential of GLS inhibition. In an attempt to identify more potent GLS inhibitors with improved drug-like molecular properties, a series of BPTES analogs were synthesized and evaluated. Our structure-activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aqueous solubility. One of the analogs, N-(5-{2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl}-[1,3,4]thiadiazol-2-yl)-2-phenyl-acetamide 6, exhibited similar potency and better solubility relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.
- Published
- 2012
- Full Text
- View/download PDF
31. Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis.
- Author
-
Rahn KA, Watkins CC, Alt J, Rais R, Stathis M, Grishkan I, Crainiceau CM, Pomper MG, Rojas C, Pletnikov MV, Calabresi PA, Brandt J, Barker PB, Slusher BS, and Kaplin AI
- Subjects
- Adult, Analysis of Variance, Animals, Cognitive Dysfunction etiology, Dipeptides metabolism, Female, Flow Cytometry, Humans, Magnetic Resonance Spectroscopy, Male, Mass Spectrometry, Mice, Mice, Inbred C57BL, Neuropsychological Tests, Organophosphorus Compounds, Cognitive Dysfunction enzymology, Encephalomyelitis, Autoimmune, Experimental complications, Glutamate Carboxypeptidase II antagonists & inhibitors, Hippocampus metabolism, Multiple Sclerosis complications
- Abstract
Half of all patients with multiple sclerosis (MS) experience cognitive impairment, for which there is no pharmacological treatment. Using magnetic resonance spectroscopy (MRS), we examined metabolic changes in the hippocampi of MS patients, compared the findings to performance on a neurocognitive test battery, and found that N-acetylaspartylglutamate (NAAG) concentration correlated with cognitive functioning. Specifically, MS patients with cognitive impairment had low hippocampal NAAG levels, whereas those with normal cognition demonstrated higher levels. We then evaluated glutamate carboxypeptidase II (GCPII) inhibitors, known to increase brain NAAG levels, on cognition in the experimental autoimmune encephalomyelitis (EAE) model of MS. Whereas GCPII inhibitor administration did not affect physical disabilities, it increased brain NAAG levels and dramatically improved learning and memory test performance compared with vehicle-treated EAE mice. These data suggest that NAAG is a unique biomarker for cognitive function in MS and that inhibition of GCPII might be a unique therapeutic strategy for recovery of cognitive function.
- Published
- 2012
- Full Text
- View/download PDF
32. Development of a high-throughput fluorescence polarization assay to identify novel ligands of glutamate carboxypeptidase II.
- Author
-
Alquicer G, Sedlák D, Byun Y, Pavlícek J, Stathis M, Rojas C, Slusher B, Pomper MG, Bartunek P, and Barinka C
- Subjects
- Antigens, Surface genetics, Antigens, Surface metabolism, Fluorescent Dyes chemical synthesis, Glutamate Carboxypeptidase II genetics, Glutamate Carboxypeptidase II metabolism, Humans, Ligands, Protein Binding, Small Molecule Libraries pharmacology, Fluorescence Polarization methods, Glutamate Carboxypeptidase II antagonists & inhibitors, High-Throughput Screening Assays methods
- Abstract
Glutamate carboxypeptidase II (GCPII) is an important target for therapeutic and diagnostic interventions aimed at prostate cancer and neurologic disorders. Here we describe the development and optimization of a high-throughput screening (HTS) assay based on fluorescence polarization (FP) that facilitates the identification of novel scaffolds inhibiting GCPII. First, we designed and synthesized a fluorescence probe based on a urea-based inhibitory scaffold covalently linked to a Bodipy TMR fluorophore (TMRGlu). Next, we established and optimized conditions suitable for HTS and evaluated the assay robustness by testing the influence of a variety of physicochemical parameters (e.g., pH, temperature, time) and additives. Using known GCPII inhibitors, the FP assay was shown to be comparable to benchmark assays established in the field. Finally, we evaluated the FP assay by HTS of a 20 000-compound library. The novel assay presented here is robust, highly reproducible (Z' = 0.82), inexpensive, and suitable for automation, thus providing an excellent platform for HTS of small-molecule libraries targeting GCPII.
- Published
- 2012
- Full Text
- View/download PDF
33. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.
- Author
-
Stathis M, Pietra C, Rojas C, and Slusher BS
- Subjects
- Animals, Cell Line, Tumor, Drug Synergism, Palonosetron, Receptors, Neurokinin-1 physiology, Isoquinolines pharmacology, Neurokinin-1 Receptor Antagonists, Pyridines pharmacology, Quinuclidines pharmacology, Serotonin 5-HT3 Receptor Antagonists pharmacology, Substance P antagonists & inhibitors, Substance P pharmacology
- Abstract
Netupitant is a potent and selective NK(1) receptor antagonist under development in combination with a fixed dose of palonosetron for the prevention of chemotherapy induced nausea and vomiting. Palonosetron is a 5-HT(3) receptor antagonist approved for both the prevention of acute and delayed chemotherapy induced nausea and vomiting after moderately emetogenic chemotherapy. Accumulating evidence suggests that substance P (SP), a ligand acting largely on tachykinin (NK(1)) receptors, is the dominant mediator of delayed emesis. Interestingly, palonosetron does not bind to the NK(1) receptor so that the mechanism behind palonosetron's unique efficacy against delayed emesis is not clear. Palonosetron exhibits a distinct ability among 5-HT(3) receptor antagonists to inhibit crosstalk between NK(1) and 5-HT(3) receptor signaling pathways. The objective of the current work was to determine if palonosetron's ability to inhibit receptor signaling crosstalk would influence netupitant's inhibition of the SP-mediated response when the two drugs are dosed together. We first studied the inhibition of SP-induced Ca(2+) mobilization in NG108-15 cells by palonosetron, ondansetron and granisetron. Unexpectedly, in the absence of serotonin, palonosetron inhibited the SP-mediated dose response 15-fold; ondansetron and granisetron had no effect. Netupitant also dose-dependently inhibited the SP response as expected from an NK1 receptor antagonist. Importantly, when both palonosetron and netupitant were present, they exhibited an enhanced inhibition of the SP response compared to either of the two antagonists alone. The results further confirm palonosetron's unique pharmacology among 5-HT(3) receptor antagonists and suggest that it can enhance the prevention of delayed emesis provided by NK(1) receptor antagonists., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
34. Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds.
- Author
-
Stoermer D, Vitharana D, Hin N, Delahanty G, Duvall B, Ferraris DV, Grella BS, Hoover R, Rojas C, Shanholtz MK, Smith KP, Stathis M, Wu Y, Wozniak KM, Slusher BS, and Tsukamoto T
- Subjects
- Animals, Benzoates pharmacokinetics, Benzoates therapeutic use, Chemistry Techniques, Synthetic, Enzyme Inhibitors pharmacokinetics, Enzyme Inhibitors therapeutic use, Humans, Inhibitory Concentration 50, Neuralgia drug therapy, Rats, Benzoates chemical synthesis, Benzoates pharmacology, Drug Design, Enzyme Inhibitors chemical synthesis, Enzyme Inhibitors pharmacology, Glutamate Carboxypeptidase II antagonists & inhibitors
- Abstract
A series of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors have been synthesized with either a 3-(mercaptomethyl)benzoic acid or 2-(2-mercaptoethyl)benzoic acid scaffold. Potent inhibitors were identified from each of the two scaffolds with IC(50) values in the single-digit nanomolar range, including 2-(3-carboxybenzyloxy)-5-(mercaptomethyl)benzoic acid 27c and 3-(2-mercaptoethyl)biphenyl-2,3'-dicarboxylic acid 35c. Compound 35c was found to be metabolically stable and selective over a number of targets related to glutamate-mediated neurotransmission. Furthermore, compound 35c was found to be orally available in rats and exhibited efficacy in an animal model of neuropathic pain following oral administration.
- Published
- 2012
- Full Text
- View/download PDF
35. Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies.
- Author
-
Rojas C, Stathis M, Polydefkis M, Rudek MA, Zhao M, Ebenezer GJ, and Slusher BS
- Subjects
- Animals, Biomarkers metabolism, Biopsy, Carboxypeptidases antagonists & inhibitors, Chromatography, Liquid, Dose-Response Relationship, Drug, Humans, Male, Mass Spectrometry, Organophosphorus Compounds administration & dosage, Organophosphorus Compounds analysis, Rats, Rats, Wistar, Sciatic Nerve drug effects, Sciatic Nerve enzymology, Skin drug effects, Time Factors, Carboxypeptidases metabolism, Organophosphorus Compounds pharmacology, Skin enzymology, Skin pathology
- Abstract
Background: Glutamate excitotoxicity is thought to be involved in the pathogenesis of neurodegenerative disease. One potential source of glutamate is N-acetyl-aspartyl-glutamate (NAAG) which is hydrolyzed to glutamate and N-acetyl-aspartate (NAA) in a reaction catalyzed by glutamate carboxypeptidase (GCP). As a result, GCP inhibition is thought to be beneficial for the treatment of neurodegenerative diseases where excess glutamate is presumed pathogenic. Both pharmacological and genetic inhibition of GCP has shown therapeutic utility in preclinical models and this has led to GCP inhibitors being pursued for the treatment of nervous system disorders in human clinical trials. Specifically, GCP inhibitors are currently being developed for peripheral neuropathy and neuropathic pain. The purpose of this study was to develop a pharmacodynamic (PD) marker assay to use in clinical development. The PD marker will determine the effect of GCP inhibitors on GCP enzymatic activity in human skin as measure of inhibition in peripheral nerve and help predict drug doses required to elicit pharmacologic responses., Methods: GCP activity was first characterized in both human skin and rat paw pads. GCP activity was then monitored in both rodent paw pads and sciatic nerve from the same animals following peripheral administration of various doses of GCP inhibitor. Significant differences among measurements were determined using two-tailed distribution, equal variance student's t test., Results: We describe for the first time, a direct and quantifiable assay to evaluate GCP enzymatic activity in human skin biopsy samples. In addition, we show that GCP activity in skin is responsive to pharmacological manipulation; GCP activity in rodent paws was inhibited in a dose response manner following peripheral administration of a potent and selective GCP inhibitor. Inhibition of GCP activity in rat paw pads was shown to correlate to inhibition of GCP activity in peripheral nerve., Conclusion: Monitoring GCP activity in human skin after administration of GCP inhibitors could be readily used as PD marker in the clinical development of GCP inhibitors. Enzymatic activity provides a simple and direct measurement of GCP activity from tissue samples easily assessable in human subjects.
- Published
- 2011
- Full Text
- View/download PDF
36. The discovery and structure-activity relationships of indole-based inhibitors of glutamate carboxypeptidase II.
- Author
-
Grella B, Adams J, Berry JF, Delahanty G, Ferraris DV, Majer P, Ni C, Shukla K, Shuler SA, Slusher BS, Stathis M, and Tsukamoto T
- Subjects
- Carboxylic Acids, Drug Evaluation, Preclinical, Glutamate Carboxypeptidase II metabolism, Indoles chemical synthesis, Indoles pharmacology, Protease Inhibitors chemical synthesis, Protease Inhibitors pharmacology, Structure-Activity Relationship, Glutamate Carboxypeptidase II antagonists & inhibitors, Indoles chemistry, Protease Inhibitors chemistry
- Abstract
A series of N-substituted 3-(2-mercaptoethyl)-1H-indole-2-carboxylic acids were synthesized as inhibitors of glutamate carboxypeptidase II (GCPII). Those containing carboxybenzyl or carboxyphenyl groups at the N-position exhibited potent inhibitory activity against GCPII. These indole-based compounds represent the first example of achiral GCPII inhibitors and demonstrate greater tolerance of the GCPII active site for ligands with significant structural difference from the endogenous substrate, N-acetyl-aspartylglutamate., (Copyright © 2010. Published by Elsevier Ltd.)
- Published
- 2010
- Full Text
- View/download PDF
37. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.
- Author
-
Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, and Slusher BS
- Subjects
- Action Potentials drug effects, Animals, Antiemetics administration & dosage, Antiemetics pharmacology, Antineoplastic Agents adverse effects, Calcium metabolism, Cell Line, Cisplatin adverse effects, Disease Models, Animal, Dose-Response Relationship, Drug, Isoquinolines administration & dosage, Isoquinolines pharmacology, Male, Neurokinin-1 Receptor Antagonists, Neurons drug effects, Neurons metabolism, Nodose Ganglion cytology, Nodose Ganglion drug effects, Nodose Ganglion metabolism, Palonosetron, Quinuclidines administration & dosage, Quinuclidines pharmacology, Rats, Rats, Sprague-Dawley, Receptors, Neurokinin-1 biosynthesis, Receptors, Serotonin, 5-HT3 biosynthesis, Serotonin metabolism, Vomiting chemically induced, Vomiting metabolism, Antiemetics therapeutic use, Isoquinolines therapeutic use, Quinuclidines therapeutic use, Serotonin 5-HT3 Receptor Antagonists, Substance P physiology, Vomiting drug therapy
- Abstract
Palonosetron is the only 5-HT(3) receptor antagonist approved for the treatment of delayed chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy. Accumulating evidence suggests that substance P (SP), the endogenous ligand acting preferentially on neurokinin-1 (NK-1) receptors, not serotonin (5-HT), is the dominant mediator of delayed emesis. However, palonosetron does not bind to the NK-1 receptor. Recent data have revealed cross-talk between the NK-1 and 5HT(3) receptor signaling pathways; we postulated that if palonosetron differentially inhibited NK-1/5-HT(3) cross-talk, it could help explain its efficacy profile in delayed emesis. Consequently, we evaluated the effect of palonosetron, granisetron, and ondansetron on SP-induced responses in vitro and in vivo. NG108-15 cells were preincubated with palonosetron, granisetron, or ondansetron; antagonists were removed and the effect on serotonin enhancement of SP-induced calcium release was measured. In the absence of antagonist, serotonin enhanced SP-induced calcium-ion release. After preincubation with palonosetron, but not ondansetron or granisetron, the serotonin enhancement of the SP response was inhibited. Rats were treated with cisplatin and either palonosetron, granisetron, or ondansetron. At various times after dosing, single neuronal recordings from nodose ganglia were collected after stimulation with SP; nodose ganglia neuronal responses to SP were enhanced when the animals were pretreated with cisplatin. Palonosetron, but not ondansetron or granisetron, dose-dependently inhibited the cisplatin-induced SP enhancement. The results are consistent with previous data showing that palonosetron exhibits distinct pharmacology versus the older 5-HT(3) receptor antagonists and provide a rationale for the efficacy observed with palonosetron in delayed CINV in the clinic.
- Published
- 2010
- Full Text
- View/download PDF
38. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.
- Author
-
Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, and Slusher BS
- Subjects
- Animals, Cell Line, Cell Membrane drug effects, Cell Membrane metabolism, Cell-Free System drug effects, Cell-Free System metabolism, Granisetron pharmacology, Humans, Isoquinolines chemistry, Isoquinolines metabolism, Isotope Labeling, Microscopy, Fluorescence, Palonosetron, Protein Transport drug effects, Quinuclidines chemistry, Quinuclidines metabolism, Substrate Specificity, Time Factors, Tritium chemistry, Isoquinolines pharmacology, Quinuclidines pharmacology, Receptors, Serotonin, 5-HT3 metabolism, Serotonin 5-HT3 Receptor Antagonists
- Abstract
Palonosetron is a 5-HT(3) receptor antagonist that has demonstrated superiority in preventing both acute and delayed emesis when compared to older first generation 5-HT(3) receptor antagonists. The objective of this work was to determine if palonosetron exhibits unique molecular interactions with the 5-HT(3) receptor that could provide a scientific rationale for observed clinical efficacy differences. Previously, we showed that palonosetron exhibits allosteric binding and positive cooperativity to the 5-HT(3) receptor in contrast to ondansetron and granisetron which exhibit simple bimolecular binding. The present work shows, through several independent experiments, that palonosetron uniquely triggers 5-HT(3) receptor internalization and induces prolonged inhibition of receptor function. After 24h incubation followed by dissociation conditions, [(3)H]palonosetron remained associated with whole cells but not to cell-free membranes (P<0.001). [(3)H]Palonosetron's binding to cells was resistant to both protease and acid treatments designed to denature cell surface proteins suggesting that the receptor complex was inside the cells rather than at the surface. Cells pretreated with unlabeled palonosetron subsequently exhibited reduced cell surface 5-HT(3) receptor binding. Palonosetron-triggered receptor internalization was visualized by confocal fluorescence microscopy using cells transfected with 5-HT(3) receptor fused to enhanced cyan fluorescent protein. In contrast, granisetron and ondansetron showed minimal to no effect on receptor internalization or prolonged inhibition of receptor function. These experiments may provide a pharmacological basis for differences noted in published clinical trials comparing palonosetron to other 5-HT(3) receptor antagonists.
- Published
- 2010
- Full Text
- View/download PDF
39. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor.
- Author
-
Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, and Slusher B
- Subjects
- Animals, Binding Sites, Calcium metabolism, Cell Line, Granisetron, Ondansetron, Palonosetron, Postoperative Nausea and Vomiting prevention & control, Radioligand Assay, Serotonin 5-HT3 Receptor Antagonists, Transfection, Antiemetics metabolism, Isoquinolines metabolism, Quinuclidines metabolism, Receptors, Serotonin, 5-HT3 metabolism
- Abstract
Background: Palonosetron is a 5-HT(3)-receptor antagonist (5-HT(3)-RA) that has been shown to be superior to other 5-HT(3)-RAs in phase III clinical trials for the prevention of acute, delayed, and overall chemotherapy-induced nausea and vomiting. The improved clinical efficacy of palonosetron may be due, in part, to its more potent binding and longer half-life. However, these attributes alone are not sufficient to explain the results with palonosetron. We sought to elucidate additional differences among 5-HT(3)-RAs that could help explain the observations in the clinic., Methods: Receptor site saturation binding experiments were performed with [3H] palonosetron, [3H] granisetron, and [3H] ondansetron to obtain the corresponding Scatchard analyses and Hill coefficients. Diagnostic equilibrium binding experiments and kinetic dissociation experiments were conducted to examine competitive versus potential allosteric interactions between ondansetron, granisetron and palonosetron and the 5-HT(3) receptor. Finally, the long-term effect of the three antagonists on receptor function as measured by Ca2+ influx in HEK 293 cells expressing the 5-HT(3)-receptor was compared., Results: Analyses of binding isotherms using both Scatchard and Hill plots suggested positive cooperativity for palonosetron and simple bimolecular binding for both granisetron and ondansetron. Equilibrium diagnostic tests discriminated differential effects of palonosetron on [3H] ligand binding indicating that palonosetron was an allosteric antagonist whereas granisetron and ondansetron were competitive antagonists. Using dissociation rate strategies, palonosetron was shown to be an allosteric modifier that accelerated the rate of dissociation from the receptor of both granisetron and ondansetron. Differences in the binding mode of palonosetron to the 5-HT(3) receptor were shown to have an impact on receptor function. In these experiments, cells were incubated with each antagonist, followed by infinite dilutions and dissociation for 2.5 h; cells previously incubated with either granisetron or ondansetron showed calcium-ion influx similar to control cells that had not been exposed to a 5-HT(3) receptor antagonist. In contrast, substantial inhibition of calcium-ion influx was observed in cells that had been incubated with palonosetron., Conclusions: Palonosetron exhibited allosteric binding and positive cooperativity when binding to the 5-HT(3) receptor. Palonosetron also triggered functional effects that persisted beyond its binding to the 5-HT(3) receptor at the cell surface. Differences in binding and effects on receptor function may be relevant to the unique beneficial actions of palonosetron. To our knowledge, this is the first report showing palonosetron's interaction with the 5-HT(3) receptor at the molecular level, clearly differentiating it from other 5-HT(3)-RAs.
- Published
- 2008
- Full Text
- View/download PDF
40. High-affinity no-carrier-added 99mTc-labeled chemotactic peptides for studies of inflammation in vivo.
- Author
-
Baidoo KE, Scheffel U, Stathis M, Finley P, Lever SZ, Zhan Y, and Wagner HN Jr
- Subjects
- Amino Acid Sequence, Animals, Binding, Competitive, Chelating Agents, Chromatography, High Pressure Liquid, Female, Humans, Isotope Labeling, Leukocyte Count, Male, Mice, Molecular Structure, Monocytes metabolism, Rabbits, Radionuclide Imaging, Receptors, Formyl Peptide, Receptors, Immunologic metabolism, Receptors, Peptide metabolism, Structure-Activity Relationship, Tritium, Chemotactic Factors chemistry, Chemotactic Factors toxicity, Inflammation diagnostic imaging, Organometallic Compounds chemistry, Organometallic Compounds toxicity
- Abstract
Nalpha-for-Nle-Leu-Phe-Nle-Tyr-Lys, a chemotactic peptide that binds with high affinity to the chemoattractant receptor on granulocytes and monocytes, was labeled with 99mTc using the diaminedithiol (DADT) chelating system to coordinate the Tc. 99mTc labeling of the DADT-coupled peptide was accomplished in 84% overall yield (room temperature for 10 min) using [99mTc]glucoheptonate as the donor of prereduced Tc. HPLC analysis showed two major 99mTc-labeled peptide peaks, 99mTc-DADT-Pep-I and 99mTc-DADT-Pep-II, were obtained in a ratio of 1:0.85. Using an iodoacetamide-derivatized gel to remove unlabeled peptide from the 99mTc labeling mixtures, essentially no-carrier-added (nca) high-specific activity 99mTc-labeled chemotactic peptides were obtained. The 99Tc analogues of the peptides were synthesized (72% yield) in a similar fashion and correlated with 99mTc complexes I and II by HPLC. In vitro competitive receptor binding assays of the isolated 99Tc analogues were performed against the tritiated chemotactic peptide [3H]N-for-Met-Leu-Phe ([3H]fMLF) using isolated granulocytes. The 99Tc-derivatized peptides showed similar binding affinities to the chemoattractant receptor as the unlabeled Nalpha-for-Nle-Leu-Phe-Nle-Tyr-Lys. The nca 99mTc-labeled peptides gave high contrast images of experimental inflammation in rabbits without causing neutropenia. Thus, it is feasible to attach the Tc-DADT chelate to low-molecular weight receptor binding chemotactic peptides and retain substantial binding to the receptor. Chemotactic peptides labeled with 99mTc via the DADT ligand system have the potential for imaging focal sites of inflammation without toxic effects, an important consideration in the successful utilization of chemotactic peptide agonists.
- Published
- 1998
- Full Text
- View/download PDF
41. [125/123I]IPH: a radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors.
- Author
-
Musachio JL, Villemagne VL, Scheffel U, Stathis M, Finley P, Horti A, London ED, and Dannals RF
- Subjects
- Animals, Brain anatomy & histology, Brain Chemistry, Dose-Response Relationship, Drug, Iodine Radioisotopes, Ligands, Male, Mice, Papio, Tissue Distribution, Tomography, Emission-Computed, Single-Photon, Bridged Bicyclo Compounds, Heterocyclic pharmacokinetics, Nicotinic Agonists pharmacokinetics, Pyridines pharmacokinetics, Receptors, Nicotinic drug effects
- Abstract
Tomographic imaging of central nicotinic acetylcholine receptors (nAChRs) via single photon emission computed tomography (SPECT) has been hampered by the lack of a radioligand with suitable in vivo binding characteristics. Therefore, a novel analog of epibatidine, (+/-)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]heptane (IPH), labeled with [(125)I] or [(123)I] was evaluated as an in vivo marker of central nicotinic acetylcholine receptors (nAChRs). [(125)I]IPH showed substantial brain penetration (4.2% of the injected dose at 30 min) and a cerebral biodistribution in mice consistent with the in vivo labeling of nAChRs (% injected dose/gram of thalamus, superior colliculi >> cerebellum). [(125)I]IPH binding sites were shown to be saturable with unlabeled IPH (ED50 approximately 1 microg/kg). The uptake of [(125)I]IPH was blocked significantly by the nicotinic agonists, cytisine, lobeline, and (-)-nicotine, but not by the noncompetitive nAChR antagonist, mecamylamine. Antagonists of muscarinic (scopolamine), serotonin (ketanserin), and opioid (naloxone) receptors had no significant effect on [(125)I]IPH binding. A preliminary SPECT imaging study with [(123)I]IPH in a baboon showed [(123)I]IPH to localize in nAChR-rich areas of brain (thalamus > frontal cortex > cerebellum). [(123)I]IPH binding in baboon brain was also displaced (35-45% displacement) by a challenge dose of cytisine showing that a well-characterized nicotinic agonist effectively competes for [(123)I]IPH binding sites. [(123)I]IPH seems well suited for imaging studies of nAChRs and, to our knowledge, is the first SPECT agent that has allowed for the visualization of nAChRs in primate brain.
- Published
- 1997
- Full Text
- View/download PDF
42. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors.
- Author
-
Horti A, Scheffel U, Stathis M, Finley P, Ravert HT, London ED, and Dannals RF
- Subjects
- Animals, Brain metabolism, Male, Mice, Time Factors, Tissue Distribution, Brain diagnostic imaging, Bridged Bicyclo Compounds, Heterocyclic pharmacokinetics, Fluorine Radioisotopes, Pyridines pharmacokinetics, Receptors, Nicotinic analysis, Tomography, Emission-Computed
- Abstract
Unlabelled: Visualization of central nicotinic acetylcholine receptors (nAChRs) with modern PET or SPECT imaging techniques has been hampered by the lack of a radioligand with suitable in vivo binding characteristics (i.e., high target-to-nontarget ratios and kinetics appropriate for the half-life of the tracer and imaging modality used). This paper describes in vivo binding, kinetics and pharmacology of a highly potent 18F-labeled analog of epibatidine, (+/-)-exo-2-(2-[18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane ([18F]FPH), in the mouse brain with the view towards application of this tracer for PET imaging of nAChR in human brain., Methods: Fluorine-18-FPH was administered intravenously to mice, and time-activity curves were determined for several regions in the brain and other organs. Saturation and pharmacology of [18F]FPH binding was demonstrated in vivo by preinjecting unlabeled FPH or other drugs with known pharmacological action before [18F]FPH was injected. The effect of the drugs on [18F]FPH accumulation was evaluated., Results: [18F]FPH was rapidly incorporated into the mouse brain; peak activity (2.4% of the injected dose) was measured at 5 min after intravenous administration, followed by washout to 1.1% injected dose (ID) at 60 min. Highest concentrations of 18F occurred at 15 min in areas known to contain high densities of nAChR ¿e.g., thalamus [9.7% of injected dose per gram tissue (ID/g¿] and superior colliculus (8.3% ID/g)]. Accumulation of the 18F tracer in hippocampus, striatum, hypothalamus and cortical areas was intermediate (5.0, 5.6, 4.2 and 5.6% ID/g, respectively) and low in the cerebellum (2.8% ID/g). The distribution of [18F]FPH in the mouse brain matched that of other in vivo nAChR probes such as 3H-labeled epibatidine or norchloroepibatidine, [3H](-)-nicotine and [3H]cytisine and that of nAChR densities determined in postmortem autoradiographic studies in rodents. Preinjection of blocking doses of unlabeled epibatidine, (-)-nicotine, lobeline and cytisine significantly inhibited [18F]FPH binding in thalamus and superior colliculus, but not in cerebellum, whereas drugs that interact with binding sites other than acetylcholine recognition sites of nAChR (e.g., mecamylamine, scopolamine, N-methylspiperone and ketanserin) had no effect on [18F]FPH accumulation in any of the brain regions examined., Conclusion: Fluorine-18-FPH labels nAChR in vivo in the mouse brain. Because of its high uptake into the brain and high ratios of specific-to-nonspecific binding, this radioligand appears to be ideally suited for PET imaging of nAChR in the mammalian brain.
- Published
- 1997
43. Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3 beta-(4-[125I]iodophenyl) tropan-2 beta-carboxylic acid isopropyl ester ([125I]RTI-121).
- Author
-
Lever JR, Scheffel U, Stathis M, Seltzman HH, Wyrick CD, Abraham P, Parham K, Thomas BF, Boja JW, Kuhar MJ, and Carroll FI
- Subjects
- Amphetamine pharmacology, Analysis of Variance, Animals, Carrier Proteins analysis, Carrier Proteins drug effects, Chromatography, High Pressure Liquid, Cocaine metabolism, Cocaine pharmacokinetics, Dopamine metabolism, Dopamine Plasma Membrane Transport Proteins, Isotope Labeling methods, Kinetics, Ligands, Male, Mice, Mice, Inbred Strains, Molecular Structure, Tissue Distribution, Brain metabolism, Carrier Proteins metabolism, Cocaine analogs & derivatives, Iodine Radioisotopes, Membrane Glycoproteins, Membrane Transport Proteins, Nerve Tissue Proteins
- Abstract
A selective ligand for the dopamine transporter 3 beta-(4-iodophenyl)tropan-2 beta-carboxylic acid isopropyl ester (RTI-121) has been labeled with iodine-125 by electrophilic radioiododestannylation. The [125I]RTI-121 was obtained in good yield (86 +/- 7%, n = 3) with high radiochemical purity (> 99%) and specific radioactivity (1210-1950 mCi/mumol). After i.v. administration of [125I]RTI-121 to mice, the rank order of regional brain tissue radioactivity (striatum > olfactory tubercles > > cortex, hippocampus, thalamus, hypothalamus, cerebellum) was consistent with dopamine transporter labeling. Specific in vivo binding in striatum and olfactory tubercles was saturable, and was blocked by the dopamine transporter ligands GBR 12,909 and (+/-)-nomifensine. By contrast, binding was not reduced by paroxetine, a serotonin transporter inhibitor, or desipramine, a norepinephrine transporter inhibitor. A variety of additional drugs having high affinities for recognition sites other than the neuronal dopamine transporter also had no effect. The [125I]RTI-121 binding in striatum and olfactory tubercles was inhibited by d-amphetamine in dose-dependent fashion. Nonmetabolized radioligand represents 85% of the signal observed in extracts of whole mouse brain. Thus, [125I]RTI-121 is readily prepared, and is a useful tracer for dopamine transporter studies in vivo.
- Published
- 1996
- Full Text
- View/download PDF
44. In vivo labeling of delta opioid receptors in mouse brain by [3H]benzylidenenaltrexone, a ligand selective for the delta 1 subtype.
- Author
-
Lever JR, Stathis M, Kinter CM, and Scheffel U
- Subjects
- Animals, Benzylidene Compounds pharmacokinetics, Corpus Striatum metabolism, Male, Mice, Naltrexone metabolism, Naltrexone pharmacokinetics, Naltrexone pharmacology, Radioligand Assay, Receptors, Opioid, delta antagonists & inhibitors, Receptors, Opioid, delta drug effects, Tritium, Benzylidene Compounds metabolism, Naltrexone analogs & derivatives, Receptors, Opioid, delta metabolism
- Abstract
(E)-7-Benzylidenenaltrexone (BNTX) is a selective ligand for the putative delta 1 (delta 1) opioid receptor. To explore the feasibility of labeling delta 1 sites in vivo; we determined the cerebral distribution of radioactivity after systemic administration of [3H]BNTX to CD1 mice. Uptake was highest in striatum and lowest in cerebellum throughout the 4 hr time course. Specific radioligand binding, approximated as the difference in radioactivity concentrations between striatum and cerebellum, peaked at 0.32 percent injected dose/g at 30 min and comprised a modest 23% of total striatal radioactivity. For seven brain regions, radioactivity concentrations correlated with delta site densities known from prior in vitro studies (rS = 0.79, p = 0.03), and also with the uptake of N1'-([11C]methyl)naltrindole in vivo (rS = 0.78, p = 0.04) in mice. Specific binding in striatum, olfactory tubercles and cortical regions was saturable by BNTX, and was inhibited stereoselectively by the optical isomers of naloxone. Naltrindole and naltriben (NTB), delta antagonists, blocked 65-99% of [3H]BNTX specific binding at a dosage of 5.0 mumol/kg. Similar doses of the mu antagonist cyprodime, or the kappa agonist U50,488H, did not inhibit binding. Adjusted for the four-fold greater brain penetration of NTB relative to BNTX, dose-response studies suggested that delta 1 selective BNTX (ED50 = 1.51 mumol/kg) was 50% more potent than delta 2 selective NTB (ED50 = 0.56 mumol/kg) in blocking specific [3H]BNTX binding in striatum. In CXBK mice, a strain with functional delta 1 but not delta 2 receptors in antinociceptive assays, radioligand uptake and distribution proved similar to that in CD1 mice. In sum, [3H]BNTX labels murine delta opioid receptors in vivo with a low extent of specific binding. The data is consistent with, but not conclusive for, selective labeling of the delta 1 subtype.
- Published
- 1996
- Full Text
- View/download PDF
45. [3H]A-69024: a non-benzazepine ligand for in vitro and in vivo studies of dopamine D1 receptors.
- Author
-
Kassiou M, Scheffel UA, Musachio JL, Stathis M, and Dannals RF
- Subjects
- Animals, Benzazepines pharmacology, Corpus Striatum metabolism, Male, Mice, Papaverine metabolism, Rats, Rats, Sprague-Dawley, Tetrahydroisoquinolines, Dopamine Antagonists metabolism, Papaverine analogs & derivatives, Receptors, Dopamine D1 metabolism
- Abstract
[3H]A-69024 has been prepared as a radioligand for studying the dopamine D1 receptor. [3H]A-69024 binds to rat striatal membranes with a KD = 14.3 +/- 3.2 nM (mean +/- SEM; n = 3) and Bmax = 63.5 +/- 12.8 fmol/mg wet tissue (1.8 +/- 0.3 pmol/mg protein). This ligand binds to only one site with a Hill coefficient close to unity. The in vivo biodistribution of [3H]A-69024 showed a high uptake in the striatum (5.9% ID/g) at 5 min followed by clearance. As a measure of specificity, the striatum/cerebellar ratio reached a maximum of 6.7 at 30 min post-injection. Pre-treatment with the D1 antagonist R(+)SCH 23390 (1 mg/kg) reduced this ratio to unity. The dopamine antagonist (+)butaclamol and unlabeled A-69024 inhibited striatal uptake by 70 and 51%, respectively. Spiperone (D2/5-HT2A) and ketanserin (5-HT2A/5-HT2C) at doses of 1 mg/kg had no inhibitory effect on [3H]A-69024 uptake in the striatum; however, increased uptake of [3H]A-69024 by > 30% in the whole brain was observed. The selectivity and affinity of [3H]A-69024 suggests that this non-benzazepine radioligand may be useful for in vitro and in vivo studies of the dopamine D1 receptor.
- Published
- 1995
- Full Text
- View/download PDF
46. (+)-[C-11]-cis-N-benzyl-normetazocine: a selective ligand for sigma receptors in vivo.
- Author
-
Musachio JL, Scheffel U, Stathis M, Ravert HT, Mathews WB, and Dannals RF
- Subjects
- Animals, Binding, Competitive, Brain diagnostic imaging, Carbon Radioisotopes, Cyclazocine metabolism, Cyclazocine pharmacokinetics, Haloperidol pharmacology, Kinetics, Ligands, Male, Mice, Organ Specificity, Pentazocine pharmacology, Phencyclidine pharmacology, Piperidines pharmacology, Receptors, sigma analysis, Receptors, sigma antagonists & inhibitors, Spiperone pharmacology, Stereoisomerism, Tissue Distribution, Tomography, Emission-Computed, Brain metabolism, Cyclazocine analogs & derivatives, Receptors, sigma metabolism
- Abstract
The in vivo biodistribution profile of the novel sigma (sigma) receptor ligand (+)-[C-11]-cis-N-benzyl-normetazocine ([C-11]-(+)-NBnNM) in mouse brain was examined. This radioligand displayed high brain uptake and a distribution consistent with the density of sigma receptors. Brain radioactivity levels peaked at 15 min postinjection and were largely maintained (ca. 80% of maximal values) up to 90 min postinjection. Pretreatment with several different sigma ligands (haloperidol, (+)-pentazocine, DuP 734, ifenprodil) effectively inhibited [C-11]-(+)-NBnNM binding in a dose-dependent manner in all brain regions. [C-11]-(+)-NBnNM binding sites were shown to be saturable with unlabeled (+)-NBnNM (ED50 = 0.02 mg/kg) and enantioselectively inhibited by the optical isomers of pentazocine. A blocking dose of the dopamine D2 antagonist spiperone (1 mg/kg) did not significantly inhibit [C-11]-(+)-NBnNM binding. Pretreatment with the phencyclidine (PCP) blocker 1-[1-(2-thienyl)cyclohexyl] piperidine (TCP) did not significantly alter total brain tissue radioactivity. Thus, [C-11]-(+)-NBnNM binds with high specificity and selectivity to sigma receptors in vivo and offers excellent potential to study sigma receptors in living human brain via positron emission tomography.
- Published
- 1994
- Full Text
- View/download PDF
47. In vivo biodistribution of two [18F]-labelled muscarinic cholinergic receptor ligands: 2-[18F]- and 4-[18F]-fluorodexetimide.
- Author
-
Wilson AA, Scheffel UA, Dannals RF, Stathis M, Ravert HT, and Wagner HN Jr
- Subjects
- Animals, Atropine metabolism, Cerebellum metabolism, Cerebral Cortex metabolism, Corpus Striatum metabolism, Dexetimide metabolism, Dexetimide pharmacokinetics, Male, Mice, Mice, Inbred Strains, Dexetimide analogs & derivatives, Receptors, Muscarinic metabolism, Tomography, Emission-Computed methods
- Abstract
Two [18F]-labelled analogues of the potent muscarinic cholinergic receptor (m-AChR) antagonist, dexetimide, were evaluated as potential ligands for imaging m-AChR by positron emission tomography (PET). Intravenous administration of both 2-[18F]- or 4-[18F]-fluorodexetimide resulted in high brain uptake of radioactivity in mice. High binding levels were observed in m-AChR rich areas, such as cortex and striatum, with low levels in the receptor-poor cerebellum. Uptake of radioactivity was saturable and could be blocked by pre-administration of dexetimide or atropine. Drugs with different sites of action were ineffective at blocking receptor binding. The results indicate that both radiotracers are promising candidates for use in PET studies.
- Published
- 1991
- Full Text
- View/download PDF
48. Radioiodinated D-(+)-N1-ethyl-2-iodolysergic acid diethylamide: a ligand for in vitro and in vivo studies of serotonin receptors.
- Author
-
Lever JR, Scheffel UA, Musachio JL, Stathis M, and Wagner HN Jr
- Subjects
- Animals, Brain metabolism, Brain Mapping, Ligands, Lysergic Acid Diethylamide metabolism, Mice, Radioligand Assay, Rats, Receptors, Adrenergic drug effects, Receptors, Dopamine drug effects, Receptors, Serotonin drug effects, Lysergic Acid Diethylamide analogs & derivatives, Receptors, Serotonin metabolism
- Abstract
Radioiodinated D-(+)-N1-ethyl-2-iodolysergic acid diethylamide ([125I]-EIL) has been evaluated as a ligand for in vitro and in vivo studies of cerebral serotonin 5-HT2 receptors. [125I]-EIL exhibited high affinity (KD = 209 pM) for 5-HT2 receptors with a high degree of specific binding (80-95%) in membranes from rat prefrontal cortex. The regional distribution of [125I]-EIL binding in vivo to seven areas of mouse brain correlated significantly (Rs = 0.93) with known densities of 5-HT2 receptors. In vivo specificity, defined by tissue to cerebellum radioactivity ratios, reached a maximum for frontal cortex at 6 hr (21.2) and persisted through 16 hr (8.8). Ketanserin, a 5-HT2 receptor antagonist, fully inhibited binding in a dose dependent fashion in all brain regions except cerebellum. By contrast, blockers for dopamine D2, alpha- or beta-adrenergic receptors did not significantly inhibit radioligand binding in any region. [125I]-EIL selectively labels 5-HT2 receptors in vivo with the highest specificity of any serotonergic ligand reported to date, indicating that [123I]-EIL should prove applicable to single photon emission computed tomography studies in living brain.
- Published
- 1991
- Full Text
- View/download PDF
49. In vivo labeling of the dopamine D2 receptor with N-11C-methyl-benperidol.
- Author
-
Suehiro M, Dannals RF, Scheffel U, Stathis M, Wilson AA, Ravert HT, Villemagne VL, Sanchez-Roa PM, and Wagner HN Jr
- Subjects
- Animals, Benperidol chemical synthesis, Benperidol metabolism, Benperidol pharmacokinetics, Brain diagnostic imaging, Brain metabolism, Carbon Radioisotopes, Male, Mice, Papio, Protein Binding, Receptors, Dopamine D2, Tomography, Emission-Computed, Benperidol analogs & derivatives, Receptors, Dopamine metabolism
- Abstract
A new dopamine D2 receptor radiotracer, N-11C-methyl-benperidol (11C-NMB), was prepared and its in vivo biologic behavior in mice and a baboon was studied. Carbon-11-NMB was determined to bind to specific sites characterized as dopamine D2 receptors. The binding was saturable, reversible, and stereospecific. Kinetic studies in the dopamine D2 receptor-rich striatum showed that 11C-NMB was retained five times longer than in receptor-devoid regions, resulting in a high maximum striatal-to-cerebellar ratio of 11:1 at 60 min after injection. From frontal cortex and cortex, on the other hand, the tracer washed out as rapidly as it did from cerebellum, resulting in tissue-to-cerebellar ratios close to one in these regions at any time after injection. Blocking studies confirmed the specificity and selectivity of the 11C-NMB binding to the dopamine D2 receptor. A PET study with 11C-NMB of the baboon brain revealed highly selective labeling of dopamine D2 receptor sites which was blocked by preinjection of raclopride.
- Published
- 1990
50. In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors.
- Author
-
Lever JR, Scheffel UA, Stathis M, Musachio JL, and Wagner HN Jr
- Subjects
- Animals, Binding, Competitive, Cerebellum metabolism, Corpus Striatum metabolism, Culture Techniques, Frontal Lobe metabolism, Ligands, Male, Mice, Molecular Structure, Olfactory Bulb metabolism, Rats, Rats, Inbred Strains, Spiperone metabolism, Brain metabolism, Receptors, Dopamine metabolism, Receptors, Serotonin metabolism, Spiperone analogs & derivatives
- Abstract
Apparent affinities (Ki) of (E)- and (Z)-N-(iodoallyl)spiperone [E)- and (Z)-NIASP) for dopamine D2 and serotonin 5-HT2 receptors were determined in competition binding assays. (Z)-NIASP (Ki 0.35 nM, D2; Ki 1.75 nM, 5-HT2) proved slightly more potent and selective for D2 sites in vitro than (E)-NIASP (Ki 0.72 nM, D2; Ki 1.14 nM, 5-HT2). In vivo, radioiodinated (E)- and (Z)-[125I]-NIASP showed regional distributions in mouse brain which are consonant with prolonged binding to dopamine D2 receptors accompanied by a minor serotonergic component of shorter duration. Stereoselective, dose-dependent blockade of (E)-[125I]-NIASP uptake was found for drugs binding to dopamine D2 sites, while drugs selective for serotonin 5-HT2, alpha 1-adrenergic and dopamine D1 receptors did not inhibit radioligand binding 2 hr postinjection. Specific binding in striatal tissue was essentially irreversible over the time course of the study, and (E)-[125I]-NIASP gave a striatal to cerebellar tissue radioactivity concentration of 16.9 to 1 at 6 hr postinjection. Thus, (E)-[125I]-NIASP binds with high selectivity and specificity to dopamine D2 sites in vivo.
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.